Endologix Acquires Pounce Thrombectomy System from Surmodics

Endologix, a significant player in the medical device sector focused on vascular disease therapies, has strategically acquired the Pounce Thrombectomy System from Surmodics. This move significantly broadens Endologix's existing portfolio, which already includes prominent platforms like DETOUR, ALTO, and AFX2, by integrating a robust mechanical thrombectomy solution.

The Pounce System, which holds FDA clearance, represents a fully mechanical approach to non-surgical clot removal from peripheral arteries. Its innovative design leverages proprietary dual-basket technology and a nitinol funnel, aiming to streamline procedures for vascular interventionists. Notably, the system operates without the need for capital equipment, thrombolytic drugs, or aspiration, offering a versatile and efficient option for treating thrombi and emboli across various peripheral arterial vessel sizes, including smaller and more distal locations. The acquisition ensures continuity as the Pounce Thrombectomy System will continue to be marketed under its current FDA clearance during an integration phase.

This acquisition is particularly impactful within the peripheral vascular disease market, a segment experiencing steady growth driven by an aging population and increasing prevalence of lifestyle-related conditions. The global market for peripheral vascular devices is projected to reach tens of billions of dollars in the coming years, with thrombectomy devices being a critical component for managing acute and chronic limb ischemia. By incorporating Pounce, Endologix positions itself to offer a more comprehensive suite of solutions, addressing a wider spectrum of patient needs throughout their treatment journey.

The integration of the Pounce Thrombectomy System is expected to enhance procedural efficiency and clinical outcomes for physicians. Dr. John Liddicoat, President and CEO of Endologix, emphasized the strong strategic and clinical alignment, stating, “It serves the same physicians and patients we already work with every day and brings a clinically differentiated mechanical approach that complements our vascular intervention portfolio.” This sentiment was echoed by Dr. Venkatesh Ramaiah, Chief of Vascular and Endovascular Surgery at Pulse Cardiovascular Institute, who noted the system's "grab-and-go solution" nature and its complementary fit with Endologix's existing technologies.

As part of the transaction, Endologix will welcome a key group of Surmodics team members who have been instrumental in the development and commercialization of the Pounce platform. This infusion of talent underscores Endologix's commitment to innovation and its strategy of targeted investments to enhance its capabilities in the vascular intervention space. The company's proactive approach to expanding its offerings reflects a broader trend in the medtech industry, where strategic acquisitions are crucial for maintaining a competitive edge and addressing evolving clinical demands.

The addition of the Pounce Thrombectomy System not only strengthens Endologix's market position but also provides vascular specialists with enhanced flexibility and a more complete toolkit for managing complex vascular conditions. This strategic move is anticipated to drive further adoption of Endologix's integrated solutions, reinforcing its role as a key innovator in advancing therapies for vascular disease.